Fidaxomicin
CAS No. 873857-62-6
Fidaxomicin ( OPT-80;PAR-101 )
产品货号. M16356 CAS No. 873857-62-6
Fidaxomicin(OPT-80; PAR-101) is anew class of narrow spectrum macrocyclic antibiotic drug.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥284 | 有现货 |
|
10MG | ¥324 | 有现货 |
|
25MG | ¥437 | 有现货 |
|
50MG | ¥599 | 有现货 |
|
100MG | ¥1021 | 有现货 |
|
200MG | ¥1507 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Fidaxomicin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Fidaxomicin(OPT-80; PAR-101) is anew class of narrow spectrum macrocyclic antibiotic drug.
-
产品描述Fidaxomicin(OPT-80; PAR-101) is anew class of narrow spectrum macrocyclic antibiotic drug, selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria.Bacterial Infection Approved
-
同义词OPT-80;PAR-101
-
通路GPCR/G Protein
-
靶点Antibacterial
-
受体RNApolymerase
-
研究领域Infection
-
适应症Bacterial Infection
化学信息
-
CAS Number873857-62-6
-
分子量1058.04
-
分子式C52H74Cl2O18
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 33 mg/mL
-
SMILESO=C(O[C@@H]1[C@@H](C)O[C@@H](OC/C2=C\C=C\C[C@H](O)/C(C)=C/[C@H](CC)[C@@H](O[C@H]3[C@@H](O)[C@@H](O)[C@H](OC(C(C)C)=O)C(C)(C)O3)/C(C)=C/C(C)=C/C[C@@H]([C@H](O)C)OC2=O)[C@@H](OC)[C@H]1O)C4=C(O)C(Cl)=C(O)C(Cl)=C4CC
-
化学全称Oxacyclooctadeca-3,5,9,13,15-pentaen-2-one, 3-[[[6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-β-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-β-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
Minocycline hydrochl...
A tetracycline antibiotic with neuroprotective, antiapoptotic, anti-inflammatory and antimicrobial effects.
-
Totarol
Totarol shows antibacterial effects against several pathogenic Gram-positive bacteria, mycobacterium tuberculosis.
-
FSL 1
TLR2/6 agonist (also a putative TLR10 ligand). Activates NF-κB. Induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. Synergizes with IFNγ to induce CXCL10 release from melanoma cells.